首页 › 基金 › SILVERARC CAPITAL MANAGEMENT, LLC › TRVI

SILVERARC CAPITAL MANAGEMENT, LLC 对 TRVI 的持仓历史

TREVI THERAPEUTICS INC · 医疗保健

SILVERARC CAPITAL MANAGEMENT, LLC 在 Q2 2026 的 13F 申报中披露持有 TRVI(TREVI THERAPEUTICS INC)678,095 股,市值约 US$12.6M,约占其申报组合的 1.48%,在其申报持仓中市值排名第 21 位。 SILVERARC CAPITAL MANAGEMENT, LLC 最近 12 个申报季度中有 12 个季度披露了 TRVI 持仓,最早可追溯至 Q3 2023。

最新持仓 (Q2 2026)678.10K 股
申报持仓市值$12.65M
组合权重1.48%
首次申报Q3 2023
最近变动增持
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

SILVERARC CAPITAL MANAGEMENT, LLC 对 TRVI 的持仓演变

SILVERARC CAPITAL MANAGEMENT, LLC 于 Q3 2023 首次披露 TRVI 持仓:927,415 股(约 US$2.0M)。 该持仓在 Q2 2026 达到峰值 678,095 股,市值约 US$12.6M。 在 12 次申报中,SILVERARC CAPITAL MANAGEMENT, LLC 4 次增持、6 次减持、1 次保持不变。 最近一期申报(Q2 2026)显示持股 678,095 股、市值约 US$12.6M,环比增持 166,968 股。。 持仓曾出现大幅变动:Q3 2024 减持约 43% (随后一个季度股价上涨 23%)、Q4 2024 增持约 52% (随后一个季度股价上涨 53%)、Q2 2026 增持约 33% (随后一个季度股价下跌 23%)。

逐季持仓明细

季度股数金额变化
Q3 2023 927.41K $2.02M 新进
Q4 2023 863.88K $1.16M 减持
Q1 2024 844.24K $2.91M 减持
Q2 2024 844.24K $2.52M 持有
Q3 2024 482.57K $1.61M 减持
Q4 2024 734.23K $3.03M 增持
Q1 2025 530.00K $3.33M 减持
Q2 2025 539.59K $2.95M 增持
Q3 2025 588.79K $5.39M 增持
Q4 2025 541.24K $6.78M 减持
Q1 2026 511.13K $6.10M 减持
Q2 2026 678.10K $12.65M 增持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 TRVI 与 13F 数据

TRVI(TREVI THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 64 只申报持有 TRVI,申报仓位最大的包括:NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$95.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 TRVI 的基金

查看 TRVI 的全部基金持有人 →

常见问题

How long has SILVERARC CAPITAL MANAGEMENT, LLC held TRVI?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed TRVI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in TRVI?

As of Q2 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 678.10K shares of TRVI (TREVI THERAPEUTICS INC), valued at $12.65M, representing 1.48% of its reported portfolio and ranking #21.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling TRVI?

In the latest 13F filing (Q2 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in TRVI. The position peaked in Q2 2026 at 678.10K shares.

Which other funds hold TRVI?

Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 64 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.